Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Business licensing deal

mAbxience Sandoz emicizumab biosimilar collaboration

Analysis based on 9 articles · First reported Sep 18, 2026 · Last updated Sep 18, 2026

Sentiment
15
Attention
2
Articles
9
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The deal modestly strengthens the biosimilar growth narrative for Novartis — Sandoz and its parent-linked shareholder Fresenius (company), while adding pipeline depth for privately held mAbxience and Insud Pharma. Financial terms were not disclosed, so near-term earnings impact is limited and the market reaction is likely to be contained to sentiment around biosimilar pipeline expansion.

pharmaceuticals biotechnology healthcare

mAbxience, a majority-owned company of Fresenius (company) with partial ownership from Insud Pharma, and Novartis — Sandoz announced a licensing, development, manufacturing and commercialization agreement for a proposed emicizumab biosimilar candidate referencing Hemlibra, indicated for the treatment of hemophilia A. Under the agreement, mAbxience will be responsible for development and manufacturing of the biosimilar through its GMP-approved facilities in Spain and Argentina, while Novartis — Sandoz will hold exclusive commercialization rights globally, excluding Argentina, Uruguay, and Paraguay. Financial terms of the agreement remain confidential. The emicizumab reference market is estimated at approximately USD 5.7 billion, and hemophilia A accounts for around 80% of all hemophilia cases worldwide. Jurgen Van Broeck, Chief Executive Officer of mAbxience, said the agreement recognizes mAbxience's development and manufacturing platform and combines it with Novartis — Sandoz's global biosimilars reach. The deal expands mAbxience's pipeline into hemophilia A and rare diseases, complementing a biosimilar pipeline spanning oncology, immunology, and bone diseases, and comes as healthcare systems prepare for a wave of biologic medicines losing exclusivity.

95 mAbxience signed collaboration agreement Novartis — Sandoz
70 mAbxience granted exclusive commercialization rights Novartis — Sandoz
60 mAbxience took development manufacturing responsibility
priv
mAbxience is the development and manufacturing lead for the emicizumab biosimilar, gaining pipeline expansion into hemophilia A and rare diseases and reinforcing its biosimilars platform.
Importance 95.0 Sentiment 25.0
subs
Novartis — Sandoz secures exclusive global commercialization rights outside Argentina, Uruguay, and Paraguay, strengthening its biosimilars portfolio and long-term growth outlook.
Importance 90.0 Sentiment 20.0
stock
As majority owner of mAbxience, Fresenius gains indirect exposure to the expanded biosimilar pipeline, a modest positive for its healthcare segment.
Importance 60.0 Sentiment 10.0
priv
Insud Pharma, a partial owner of mAbxience, benefits indirectly from the strengthened biosimilars platform and pipeline expansion.
Importance 45.0 Sentiment 10.0
per
As CEO of mAbxience, Jurgen Van Broeck publicly framed the agreement as recognition of the company's development and manufacturing capabilities and its patient-access strategy.
Importance 30.0 Sentiment 5.0
cnt
Spain hosts GMP-approved manufacturing facilities where mAbxience will develop and produce the biosimilar, supporting domestic biopharma activity.
Importance 25.0 Sentiment 5.0
cnt
Argentina hosts mAbxience manufacturing facilities and is excluded from Novartis — Sandoz's commercialization rights, leaving the local market to mAbxience.
Importance 25.0 Sentiment 5.0
cnt
Uruguay is excluded from Novartis — Sandoz's exclusive commercialization territory, a minor territorial carve-out in the agreement.
Importance 10.0 Sentiment 0.0
cnt
Paraguay is excluded from Novartis — Sandoz's exclusive commercialization territory, a minor territorial carve-out in the agreement.
Importance 10.0 Sentiment 0.0
Spain related ↔ Argentina
Spain related ↔ Uruguay
Spain related ↔ Paraguay
Argentina related ↔ Uruguay
Argentina related ↔ Paraguay
Uruguay regional partners ↔ Paraguay Uruguay considers Paraguay a friendly regional partner and a significant trade partner within Mercosur, also serving as
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.